ClinicalTrials.gg
RecruitingNCT07478822Updated Apr 2, 2026

A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

A Phase 3 interventional study of Recombinant botulinum toxin type A for injection (YY001) in Upper Limb Spasticity, sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd.. Recruiting at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity

02

Conditions studied

  • Upper Limb Spasticity

Keywords

  • Botulinum Toxin
  • Recombinant Botulinum Toxin Type A
  • YY001
  • Upper limb spasticity
03

In context

Lead sponsor

Chongqing Claruvis Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years old inclusive, at the time of signing the , regardless of gender.
  2. Subjects with unilateral hemiplegia due to stroke (with a time interval of ≥ 3 months from stroke onset to enrollment) exhibiting upper limb spasticity.
  3. Subjects with Disability Assessment Scale score of at least 2 on the Principal Target of Treatment (one of four functional domains: hygiene, dressing, limb position and pain).

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to any component of the experimental drugs.
  2. Previous use of any botulinum toxin within 6 months prior to enrollment, or plan to use other botulinum toxins not specified in the study protocol during the study.
  3. Fixed contractures of the studied limb.
  4. Any medical condition that may increase the risk to the subject when using botulinum toxin type A.
  5. Need for treatment with drugs that interfere with neuromuscular function during the study.
  6. Plan or anticipate to use new antispasticity drugs during the study.
  7. History of epilepsy.
  8. Pregnant or breastfeeding women.
  9. Participation in other drug/device clinical trials within 1 month prior to enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Recombinant botulinum toxin type A (YY001)

    Multiple injection with recombinant botulinum toxin type A for injection (YY001) in upper limb spasticity

    Biological: Recombinant botulinum toxin type A for injection (YY001)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events and Serious Adverse Events

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Physician's Global Assessment (PGA) Score

    The Physician's Global Assessment is used to measure the investigator's impression of change due to treatment. The response option is a common 7-point scale that ranges from -3 = very much worse to +3 = very much improved.

    Time frame: Weeks 1, 4, 8, 12, 16, 20 and 24 after each treatment

  2. Change From Baseline in MAS Score of Primary Target Clinical Pattern

    Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed elbow or flexed wrist or clenched fist. The Modified Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 6-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).

    Time frame: Weeks 1, 4, 8, 12, 16, 20 and 24 after each treatment

  3. Response Rates on MAS Calculated for the Primary Target Clinical Pattern

    Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed elbow or flexed wrist or clenched fist. Subjects with a MAS reduction of one point were defined as responder.

    Time frame: Weeks 1, 4, 8, 12, 16, 20 and 24 after each treatment

  4. The Proportion with Disability Assessment Scale (DAS)- Principal Therapeutic Target Domain Score Reduction of ≥1 Point

    The DAS consists of the four domains hygiene, dressing, limb position and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).

    Time frame: Weeks 1, 4, 8, 12, 16, 20 and 24 after each treatment

  5. Incidence of Anti-drug Antibodies and Neutralizing Antibodies

    Time frame: Up to 48 weeks

07

Study locations

16 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 18, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478822
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 27, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Jieru Bai
Contact
bai.jieru@claruvis.com
+86 13883955310
Xiaoyun Sun
Contact
sun.xiaoyun@claruvis.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EP4 Receptor Antagonist YY001

Start the discussion